Lilly Invests $85M Upfront in Repertoire Immune Medicines for Autoimmune Therapies Partnership
Eli Lilly entered a strategic collaboration with Repertoire Immune Medicines on January 29, 2026, to develop tolerizing T cell therapies for multiple undisclosed autoimmune diseases.125
Repertoire receives $85 million upfront, up to $1.84 billion in development and commercial milestones, and tiered royalties on net sales.12345
The partnership leverages Repertoire's DECODE platform to restore immune homeostasis and achieve durable remission without broad immunosuppression.125
Repertoire, a Flagship Pioneering spinout founded in 2019, leads discovery until candidate nomination; Lilly handles clinical development, manufacturing, and commercialization.245
This is Lilly's second immunology deal in 2026, following the $1.2B acquisition of Ventyx Biosciences earlier in January.1
Repertoire has prior partnerships with Bristol Myers Squibb, Roche/Genentech, and Pfizer.2
Sources:
1. https://www.biospace.com/deals/lilly-establishes-up-to-2-7b-repertoire-deal-in-second-immune-play-of-2026
2. https://www.fiercebiotech.com/biotech/repertoire-adds-eli-lilly-its-range-big-pharma-partners-85m-upfront-autoimmune-pact
3. https://www.bioworld.com/articles/728474-repertoire-decodes-autoimmunity-in-192b-eli-lilly-deal
4. https://www.morningstar.com/news/dow-jones/202601297592/repertoire-immune-medicines-eli-lilly-set-autoimmune-collaboration
5. https://www.prnewswire.com/news-releases/repertoire-immune-medicines-announces-strategic-collaboration-with-lilly-to-develop-tolerizing-therapies-for-autoimmune-diseases-302673203.html